High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19
Copyright © 2022 Elsevier Inc. All rights reserved..
The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:241 |
|---|---|
| Enthalten in: |
Clinical immunology (Orlando, Fla.) - 241(2022) vom: 25. Aug., Seite 109068 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scordio, Mirko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.08.2022 Date Revised 01.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clim.2022.109068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342851802 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342851802 | ||
| 003 | DE-627 | ||
| 005 | 20231226015053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clim.2022.109068 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342851802 | ||
| 035 | |a (NLM)35764258 | ||
| 035 | |a (PII)S1521-6616(22)00149-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scordio, Mirko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2022 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV-1 | |
| 650 | 4 | |a HIV-1 and SARS-CoV-2 co-infection | |
| 650 | 4 | |a ISGs | |
| 650 | 4 | |a Interferon | |
| 650 | 4 | |a Neutralizing antibodies | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 700 | 1 | |a Frasca, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Santinelli, Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a Sorrentino, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Pierangeli, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Turriziani, Ombretta |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni, Claudio M |e verfasserin |4 aut | |
| 700 | 1 | |a Antonelli, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Viscidi, Raphael P |e verfasserin |4 aut | |
| 700 | 1 | |a d'Ettorre, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Scagnolari, Carolina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical immunology (Orlando, Fla.) |d 1999 |g 241(2022) vom: 25. Aug., Seite 109068 |w (DE-627)NLM098196855 |x 1521-7035 |7 nnns |
| 773 | 1 | 8 | |g volume:241 |g year:2022 |g day:25 |g month:08 |g pages:109068 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clim.2022.109068 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 241 |j 2022 |b 25 |c 08 |h 109068 | ||